LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2067 participants.

Also called NCT01763866

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,067 participants (enrolled count) (from the registry)
Sponsor
  • Amgen Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01763866
  • EudraCT 2012-001363-70
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Australia, Belgium, Canada, Czechia, Denmark, France, Germany, Hong Kong SAR China, Hungary, Italy, Mexico, Netherlands, Russia, South Africa, South Korea, Spain, Sweden, Switzerland, Taiwan, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01763866. Randomized; quadruple masking; primary purpose treatment. Start 2013-01-15 (actual); primary completion 2013-11-12 (actual). Results posted on 2015-12-22.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2
Acronym
LAPLACE-2
Condition
Hyperlipidemia
Intervention (Biological)
Evolocumab
Intervention (Drug)
Ezetimibe
Intervention (Drug)
Placebo to Evolocumab
Intervention (Drug)
Placebo to Ezetimibe
Intervention (Drug)
Atorvastatin
Intervention (Drug)
Rosuvastatin
Intervention (Drug)
Simvastatin
Lead sponsor
Amgen (class: industry)

Record details

Record id
cardio:ct-nct01763866
Content hash
5bb9f8255c409eb20235d1d4ddc780330f8d88ace1ac0f6eb09365da1625a85d